间变性淋巴瘤激酶
克拉斯
表皮生长因子受体
癌症研究
肺癌
癌症
生物
病毒癌基因
癌基因
蛋白质水解
靶向治疗
医学
肿瘤科
内科学
细胞周期
结直肠癌
酶
恶性胸腔积液
生物化学
作者
Lin J,Jingbo Zhang,Jiaqi Hu,Haixiang Qi,Hui Xu
出处
期刊:PubMed
[National Institutes of Health]
日期:2022-07-20
卷期号:25 (7): 477-481
被引量:1
标识
DOI:10.3779/j.issn.1009-3419.2022.102.19
摘要
Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors. Among the common mutation targets of non-small cell lung cancer (NSCLC), PROTAC technology has successfully achieved the effective degradation of kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK ) and other proteins in preclinical studies. PROTAC drugs with their unique event-driven advantages, are expected to overcome acquired drug resistance caused by small molecule inhibitors and show good therapeutic potential for undruggable targets, thereby providing a new strategy for the treatment of NSCLC. .【中文题目:蛋白降解靶向嵌合体在非小细胞肺癌治疗中的研究进展】 【中文摘要:蛋白降解靶向嵌合体(proteolysis targeting chimeria, PROTAC)通过利用泛素蛋白酶体途径实现对靶蛋白降解,颠覆了传统小分子抑制剂的理念。在非小细胞肺癌(non-small cell lung cancer, NSCLC)常见的突变靶点中,PROTAC技术在临床前研究中已经成功实现了鼠类肉瘤病毒癌基因(kirsten rat sarcoma viral oncogene homolog, KRAS)、表皮生长因子受体(epidermal growth factor receptor, EGFR)和间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK)等蛋白的有效降解。PROTAC药物以其事件驱动的独特优势,有望克服小分子抑制剂产生的获得性耐药的问题,并对难成药靶点展现出良好的治疗潜力,有望成为NSCLC治疗的新策略。 】 【中文关键词:蛋白降解靶向嵌合体;肺肿瘤;EGFR;ALK;KRAS】.
科研通智能强力驱动
Strongly Powered by AbleSci AI